Cancer Services Market Share

Regionally, the global cancer services market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. North America industry is expected to hold largest revenue share by 2036, impelled by higher prevalence of cancer, developing technologies for the treatment and prevention of cancer, and growing healthcare expenditure. According to a report by National Cancer Institute (NIH) in 2022, 40,000 cases of cancer were observed annually, meanwhile, 290,560 new cases of breast cancer were noticed in the USA in the same year. Additionally, 106,180 cases of colon cancer and 44,850 cases of rectal cancer also emerge in the region in 2022. Furthermore, the rising utilization of modern technology to diagnose and treat cancer is also expected to hike the growth of the market. Based on data provided by the National Library of Medicine (NLM) in 2017, about 644,000 robotic-assisted surgeries were performed in the U.S.

APAC Market Analysis

Furthermore, the global cancer services market is anticipated to grow in the Asia Pacific region during the forecast period. The growth of the market in the region is accounted to the growing geriatric population, rising cases of multiple types of cancer, and increasing awareness of the treatment of the disease.

Frequently Asked Questions (FAQ)

Increasing cases of cancer, a rising geriatric population, and growing consumption of alcohol, cigarettes, and tobacco are the major factors driving the growth of the cancer services market.

The market is anticipated to attain a CAGR of ~20% over the forecast period, i.e., 2022 - 2031.

The major players in the market are Siemens Healthcare GmbH, Fonar Corporation, Koninklijke Philips N.V., Shimadzu Corporation, Abbott Laboratories, Samsung Medison Co., Ltd., Eli Lilly and Company, Hologic, Inc., Novartis International AG, and GE Group.

Cancer Services Market Share